All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • Market intelligence reports
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 15, 2019

Diagnostics

  • Diagnostics
    • Artificial intelligence
    • Biopsy
    • Electrocardiogram
    • Genomics
    • Imaging
    • Liquid biopsy
    • Monitoring
    • Point-of-care
Home » Topics » Medical devices and technologies » Diagnostics
  • Newborn-infant-baby-feet
    December 13, 2019
    By Meg Bryant

    FDA gives nod to first newborn screening test for Duchenne muscular dystrophy

    Perkinelmer Inc., of Waltham, Mass., has won a thumbs up from the U.S. FDA for its GSP Neonatal Creatine Kinase-MM kit. The assay is the first test approved in the U.S. for help in screening newborns for Duchenne muscular dystrophy (DMD), a rare but devastating genetic disorder. While there is no known cure for DMD, earlier screening and diagnosis could lead to improvements in quality of life by enabling earlier and more personalized treatment of symptoms. The kit’s approval opens the door for states to include DMD among the battery of tests newborns typically undergo, such as phenylketonuria, cystic fibrosis and congenital heart disease.
  • December 12, 2019
    By Stacy Lawrence

    Caris launches AI-based genomic profiling test to clarify cancer of unknown primary origin

    Irving, Texas-based Caris Life Sciences Inc. has launched an AI-based genomic profiling test to better characterize cases of cancer of unknown primary origin (CUP) and atypical cases and offer appropriate treatment options. Known as the MI GPS (Genomic Profiling Similarity) Score, the analysis is based on an AI analysis of a 592-gene panel of all the clinically relevant genetic biomarkers for cancer.
  • Red-blood-cells
    December 12, 2019
    By Nuala Moran

    Enzyre, Takeda team up to develop home diagnostic device for hemophiliacs

    LONDON – Dutch startup Enzyre BV is teaming up with Takeda Pharmaceutical Co. Ltd. to complete development of a home diagnostic device that aims to make it as easy for hemophiliacs to self-test their coagulation status as it is for diabetics to monitor their blood sugar levels.
Read More

Blog Posts

  • Docgraham
    November 6, 2014
    By Omar Ford

    Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

  • August 2, 2013
    By Amanda Pedersen

    Screening saves lives, but criteria too narrow

  • July 26, 2013
    By Omar Ford

    Faster results from diagnostics could reduce anxiety

  • May 22, 2013
    By Amanda Pedersen

    Jamar Rogers: living his best life

  • May 16, 2013
    By Robert Kimball

    To sleep, perchance to analyze data?

Read More

Authors

  • Mark McCarty
  • Holland Johnson
  • Amanda Pedersen
  • Omar Ford
  • Robert Kimball
  • Nuala Moran
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Archives
    • Contact us
    • Cookie policy
    • Copyright notice
    • Privacy policy
    • Share your news
    • Staff
    • Terms of use
Follow Us

Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing